Literature DB >> 3665224

NK-mediated reduction of malignancy in human melanoma cells treated with theophylline.

I Gitelman1, W Abramow-Newerly, J C Roder.   

Abstract

Theophylline-treated cells of the human melanoma line showed an increase in NK-sensitivity in vitro and a concomitant decrease in tumorigenicity and spontaneous metastasis in Balb/c nude mice. The MeWo cells were heterogeneous and contained related subpopulations which were cloned to produce two cell lines, one hypodiploid (Cd-16) and one hypotetraploid (Ct-1). Prolonged (3 months) or short-term (4 days) treatment of these cell lines with 1 mM theophylline markedly reduced the incidence and size of tumors in Balb/c nude mice early after s.c. injection and their ability to metastasize spontaneously to the lung was also reduced. The effect was much more pronounced with Cd-16 cells, which contain amplified DNA compared to Ct-1 cells which lack DNA amplification. Part of the tumor inhibition caused by theophylline was due to natural killer (NK) cells. Thus, in vivo treatment of nude mice with anti-asialo GM1, a procedure known to remove NK cells, partially reversed the inhibitory effects of theophylline on tumor formation and generation of metastasis by Cd-16 cells. Consistent with this observation theophylline treatment enhanced the in vitro NK sensitivity of Cd-16 cells four-fold whereas Ct-1 was enhanced only slightly. The data suggest that theophylline can act preferentially on certain tumor cell subpopulations to enhance their NK-sensitive phenotype and thereby inhibit their capacity to form tumors and to metastasize in nude mice.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3665224     DOI: 10.1007/bf00120728

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  25 in total

1.  Enhanced natural killer sensitivity with concomitant clonal selection for cells bearing homogeneously staining regions in the human melanoma cell line MeWo upon induction of differentiation with theophylline.

Authors:  T Haliotis; J A Werkmeister; I Louwman; S K Liao; J Matthews; R Riopelle; H F Pross; J J Holden; B N White; A Smith
Journal:  J Natl Cancer Inst       Date:  1984-05       Impact factor: 13.506

2.  Effects of a cloned cell line with NK activity on bone marrow transplants, tumour development and metastasis in vivo.

Authors:  J F Warner; G Dennert
Journal:  Nature       Date:  1982-11-04       Impact factor: 49.962

3.  Natural killer cells mediate lysis of embryonal carcinoma cells lacking MHC.

Authors:  P Stern; M Gidlund; A Orn; H Wigzell
Journal:  Nature       Date:  1980-05-29       Impact factor: 49.962

4.  In vivo effect of anti-asialo GM1 antibody on natural killer activity.

Authors:  M Kasai; T Yoneda; S Habu; Y Maruyama; K Okumura; T Tokunaga
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

5.  Natural killer cells kill tumour cells at a given stage of differentiation.

Authors:  M Gidlund; A Orn; P K Pattengale; M Jansson; H Wigzell; K Nilsson
Journal:  Nature       Date:  1981-08-27       Impact factor: 49.962

6.  "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype.

Authors:  R Kiessling; E Klein; H Wigzell
Journal:  Eur J Immunol       Date:  1975-02       Impact factor: 5.532

7.  Spontaneous and induced primary oncogenesis in natural killer (NK)-cell-deficient beige mutant mice.

Authors:  T Haliotis; J K Ball; D Dexter; J C Roder
Journal:  Int J Cancer       Date:  1985-04-15       Impact factor: 7.396

8.  A novel transforming gene in a human malignant melanoma cell line.

Authors:  R A Padua; N Barrass; G A Currie
Journal:  Nature       Date:  1984 Oct 18-24       Impact factor: 49.962

9.  Inhibition of skin carcinogenesis in vivo by caffeine and other agents.

Authors:  F Zajdela; R Latarjet
Journal:  Natl Cancer Inst Monogr       Date:  1978-12

10.  Endocrine responsiveness in human melanocytes and melanoma cells in culture.

Authors:  B B Fuller; F L Meyskens
Journal:  J Natl Cancer Inst       Date:  1981-05       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.